The German Breast Group is researching breast cancer and implementing self-developed study concepts.
With the help of additional scientific research projects, we try to gain further insights into this disease.
We are delighted to inform you that the long-term survival analysis of the neoadjuvant GeparQuinto (GBG 44) phase III trial has been published in the Journal of Clinical Oncology.
An analysis of 802 women with triple-negative breast cancer (TNBC) from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) and GeparSixto (GBG 66) trial that investigated the association between the age at TNBC diagnosis and the presence of pathogenic germline BRCA1/2 mutations has been published in the BMC Cancer.
The first results of the BrighTNess trial designed to evaluate the addition of veliparib (a PARP inhibitor) plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) have been published in the The Lancet Oncology.
A collaborative translational study that included data from six neoadjuvant GBG trials (GeparDuo, GeparTrio, GeparQuattro, GeparQuinto, GeparSixto and GeparSepto) and investigated the role of tumour-infiltrating lymphocytes (TILs) as a prognostic factor in different subtypes of breast cancer after neoadjuvant therapy has been published in the The Lancet Oncology.
Unser Paper über PIK3CA-Mutationen ist eines der meistzitierten Paper in JCO.
Every month, we present an interesting paper.
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440